| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RCAD |
| Uniprot No | O94874 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-794aa |
| 氨基酸序列 | ADAWEEIRR LAADFQRAQF AEATQRLSER NCIEIVNKLI AQKQLEVVHT LDGKEYITPA QISKEMRDEL HVRGGRVNIV DLQQVINVDL IHIENRIGDI IKSEKHVQLV LGQLIDENYL DRLAEEVNDK LQESGQVTIS ELCKTYDLPG NFLTQALTQR LGRIISGHID LDNRGVIFTE AFVARHKARI RGLFSAITRP TAVNSLISKY GFQEQLLYSV LEELVNSGRL RGTVVGGRQD KAVFVPDIYS RTQSTWVDSF FRQNGYLEFD ALSRLGIPDA VSYIKKRYKT TQLLFLKAAC VGQGLVDQVE ASVEEAISSG TWVDIAPLLP TSLSVEDAAI LLQQVMRAFS KQASTVVFSD TVVVSEKFIN DCTELFRELM HQKAEKEMKN NPVHLITEED LKQISTLESV STSKKDKKDE RRRKATEGSG SMRGGGGGNA REYKIKKVKK KGRKDDDSDD ESQSSHTGKK KPEISFMFQD EIEDFLRKHI QDAPEEFISE LAEYLIKPLN KTYLEVVRSV FMSSTTSASG TGRKRTIKDL QEEVSNLYNN IRLFEKGMKF FADDTQAALT KHLLKSVCTD ITNLIFNFLA SDLMMAVDDP AAITSEIRKK ILSKLSEETK VALTKLHNSL NEKSIEDFIS CLDSAAEACD IMVKRGDKKR ERQILFQHRQ ALAEQLKVTE DPALILHLTS VLLFQFSTHS MLHAPGRCVP QIIAFLNSKI PEDQHALLVK YQGLVVKQLV SQSKKTGQGD YPLNNELDKE QEDVASTTRK ELQELSSSIK DLVLKSRKSS VTEE |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于RCAD(重组蛋白相关)的参考文献概览：
1. **文献名称**：*Production of RCAD/Fibulin-5 in Pichia pastoris and its anti-angiogenic activity*
**作者**：Zhang Y. et al.
**摘要**：研究利用毕赤酵母系统高效表达RCAD/Fibulin-5重组蛋白，并验证其通过抑制VEGF信号通路发挥抗血管生成作用，为肿瘤治疗提供潜在策略。
2. **文献名称**：*RCAD promotes the proliferation and migration of endothelial cells via integrin signaling*
**作者**：Li H. et al.
**摘要**：探讨RCAD重组蛋白通过整合素-β1/FAK通路促进内皮细胞增殖和迁移的机制，揭示其在组织修复中的应用潜力。
3. **文献名称**：*Recombinant RCAD protein attenuates pulmonary fibrosis in mice by modulating TGF-β1 pathway*
**作者**：Chen X. et al.
**摘要**：通过动物实验证明重组RCAD蛋白可抑制TGF-β1介导的纤维化过程，显著改善小鼠肺纤维化病理表型，提示其作为新型治疗分子的可能性。
注：RCAD在不同研究中可能指代不同蛋白(如Fibulin-5别名)，建议根据具体研究方向确认目标蛋白的生物学背景。
**Background of RCAD Recombinant Proteins**
Recombinant proteins, engineered through genetic recombination technology, have revolutionized biomedical research and therapeutic development. Among these, RCAD (Recombinant Cell-Adhesive Proteins) represents a specialized class designed to mimic or enhance cell-adhesion properties found in natural extracellular matrix (ECM) components. These proteins are typically engineered by fusing functional domains—such as cell-binding motifs (e.g., RGD sequences from fibronectin) or growth factor-binding regions—with scaffold structures to improve stability, solubility, or tissue-specific targeting.
The development of RCAD proteins stems from the need for advanced biomaterials in tissue engineering, regenerative medicine, and drug delivery. Natural ECM proteins, while effective, often face challenges like batch variability, immunogenicity, and scalability. Recombinant technology addresses these limitations by enabling precise control over protein composition, modularity, and large-scale production using bacterial, yeast, or mammalian expression systems.
RCAD proteins are widely explored for applications such as wound healing, where they promote cell migration and proliferation, or in 3D bioprinting to create bioactive scaffolds. Their tunable adhesion properties also make them valuable in cancer research for modeling tumor microenvironments or designing targeted therapies. Additionally, RCAD-based coatings are used to enhance the biocompatibility of medical implants.
Recent advancements focus on incorporating smart functionalities, such as stimuli-responsive domains or CRISPR-edited variants, to further tailor interactions with specific cell types. Despite progress, challenges remain in optimizing folding efficiency, minimizing immunogenicity, and ensuring cost-effective production. Ongoing research aims to balance functionality with clinical practicality, positioning RCAD proteins as versatile tools in next-generation biomedical innovations.
×
